PTCE Pharmacy Connect | Pharmacy Times: Recent Episodes
Pharmacy Podcast Network
Pharmacy Times Continuing Education Free Continuing Education By Pharmacists For Pharmacists https://www.pharmacytimes.org/topic?t=Podcast
Accreditation and support statement: · PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. · This activity is supported by educational grant from GlaxoSmithKline. Objectives • Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer. • Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV. · Describe the role of pharmacists in improving PrEP uptake in the United States. Faculty: Drew W. Cates, PharmD, AAHIVP, Educational Manager SynerGrx Chamblee, Georgia
Faculty, has the following financial relationships with commercial interests to disclose: Speaker's Bureau: Gilead
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023.
This activity is supported by an educational grant from ViiV. Learn more about your ad choices. Visit megaphone.fm/adchoices
Introduction of faculty and disclosures:
Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
Accreditation and support statement:
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
https://www.pharmacytimes.org/courses/multiple-myeloma-pharmacists-as-therapy-experts Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.
This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens · Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC Faculty: Paul Forsberg, PharmD, MHA, BCOP Director of Pharmacy Minnesota Oncology St. Paul, Minnesota Latha Radhakrishnan, PharmD, BCOP Clinical Oncology Pharmacist The University of Illinois Hospital and Health Sciences System Clinical Assistant Professor University of Illinois at Chicago College of Pharmacy Chicago, Illinois Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Epizyme Speakers Bureau: AstraZeneca Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Taiho, Novartis, Exelixis Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta. Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023. This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations Learn more about your ad choices. Visit megaphone.fm/adchoices
Introduction of faculty and disclosures:
Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia.
Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi.
Accreditation and support statement:
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
https://www.pharmacytimes.org/courses/multiple-myeloma-recognizing-treatment-options Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Understand the impact of Janus kinase inhibitors for the management of atopic dermatitis (AD) · Examine key safety and efficacy data on new and emerging Janus kinase inhibitors utilized for the treatment of AD and select appropriate treatments Identify the role of the pharmacist in individualizing treatment for patients with AD through patient counseling and education Faculty: Svetlana Gerzenshtein, PharmD, BCPS, CSP Clinical Pharmacist Specialist Specialty Pharmacy Department University of Chicago Medical Center Chicago, Illinois
Content Development Sarah Lant, PharmD Clinical Pharmacist Specialist UChicago Medicine Chicago, Illinois
Svetlana Gerzenshtein, PharmD, BCPS, CSP, has no financial relationships with commercial interests to disclose. Sarah Lant, PharmD, has the following relevant financial relationship with a commercial interest to disclose: Other (faculty speaker training): Lily Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Recognize the role of biomarker expression in the selection of most appropriate treatment options for patients with endometrial cancer · Review strategies for identification and management of drug-related toxicities in patients receiving therapy with immune checkpoint inhibitors, targeted agents, or combination therapy Faculty: Sarah Hayward, PharmD, BCOP Clinical Pharmacy Specialist, Gynecologic Oncology Stephenson Cancer Center at OU Health University of Oklahoma Health Science Center Oklahoma City, Oklahoma
Sarah Hayward, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant (advisory board): GSK, Seagen/Genmab
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-322-H01-P. The activity is available for CE credit through June 30, 2023.
This educational activity is supported by an educational grant from GlaxoSmithKline Learn more about your ad choices. Visit megaphone.fm/adchoices
Introduction of faculty and disclosures:
Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida.
Dr. Tobon has no relevant financial relationships with commercial interests to disclose.
Accreditation and support statement:
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.
Learn more about your ad choices. Visit megaphone.fm/adchoices
This podcast will specifically focus on clinical safety and efficacy data supporting the use of new and emerging JAK inhibitors in the management of AD. Practical counseling points for pharmacists to provide individualized care and proper selection of therapy to patients with AD who are initiating therapy with JAK inhibitors will also be discussed. Faculty experts will review audience questions and identify best practices in the management of AD. o The Role of JAK Inhibitors in the Management of Atopic Dermatitis: Latest Advances and Best Practices for the Pharmacist o Introduction of faculty, affiliations, and disclosures We would like to thank Sarah Lant, PharmD for her contribution in developing the content for this podcast. Lana Gerzenshtein, PharmD and Sarah Lant have no relevant financial relationships with commercial interests to disclose. o Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by educational grants from Incyte. Learn more about your ad choices. Visit megaphone.fm/adchoices
Introduction of faculty and disclosures:
Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida.
Dr. Tobon has no relevant financial relationships with commercial interests to disclose.
Accreditation and support statement:
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Lisa Dumkow, PharmD, BCIDP, Antimicrobial Stewardship Clinical Pharmacist, PGY-2 Infectious Diseases Pharmacy Residency Program Director, Mercy Health Saint Mary’s, Grand Rapids, MI Lacy Worden, PharmD, PGY-2 Infectious Diseases Pharmacy resident, Mercy Health Saint Mary’s, Grand Rapids MI [LP1] Dr. Dumkow & Dr. Worden have no relevant financial relationships with commercial interests to disclose
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of knowledge-based credit. This activity is supported by educational grants from GlaxoSmithKline. The educational objectives for this activity are: o Examine important milestones and recent updates in the treatment and management of COVID-19 o Interpret safety and efficacy data for recently approved, authorized, or investigational agents for the treatment of COVID-19 o Illustrate how pharmacists can assist with educating patients and other health care providers regarding the latest updates to the treatment of COVID-19 Summary statement of topic being discussed: This is a conversational interview which will focus on emerging therapies for the management of COVID-19 in the outpatient setting. A discussion around current and investigational therapies will be covered. Key takeaways and practical points will be the focus. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives
Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration
Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes
Faculty: Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM Professor Departments of Pharmacotherapy & Outcomes Science and Neurosurgery Virginia Commonwealth University, Medical College of Virginia Richmond, Virginia
Neurocritical Care Clinical Pharmacist Virginia Commonwealth University Health Richmond, Virginia
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Department of Defense
Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell
Speakers Bureau: UCB, Chiesi
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023.
This activity is supported by an educational grant from Neurelis Inc. Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy’s research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives
Describe the impact of ADHD and new non-stimulant class of ADHD treatments
Highlight the role of the pharmacist in patient counseling, monitoring and medication management in ADHD
Faculty: Sandy Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Child and Adolescent Psychiatry Department of Pharmacy Virginia Commonwealth University (VCU) Health Richmond, VA
Sandy Mullen, PharmD, BCPP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-127-H01-P. The activity is available for CE credit through March 30, 2023.
This activity is supported by an educational grant from Supernus. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives • Review the clinical and economic burdens associated with transthyretin amyloidosis (ATTR) • Recall key characteristics supporting the use of current and emerging therapies for the treatment of ATTR including mechanisms of action, clinical data, dosing, administration, and potential adverse effects
Faculty: Svetlana Goldman, PharmD, BCACP, CDCES Clinical Pharmacist UC Davis Health Sacramento, California Yvette Hellier, PharmD, BCACP Clinical Pharmacist UC Davis Health Sacramento, California
The following contributors have no relevant financial relationships with commercial interests to disclose: Faculty Svetlana Goldman, PharmD, BCACP, CDCES, and Yvette Hellier, PharmD, BCACP
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-045-H01-P. The activity is available for CE credit through February 28, 2023.
This activity is supported by an educational grant from Alnylam Pharmaceuticals. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives
Describe the impact of COVID-19 on surgical pain management
Review current postoperative pain management guidelines and emerging non-opioid treatment approaches for pain management, including safety and efficacy data on newer treatments, and key considerations for pharmacists
Faculty: Jawad N. Saleh, PharmD, BS, BCPS, BCCCP Clinical Manager of Pharmacy Services Pharmacy Department The Hospital for Special Surgery New York, New York
Faculty, has the following financial relationships with commercial interests to disclose: Jawad N. Saleh, PharmD, BS, BCPS, BCCCP, has the following relevant financial relationships with commercial interests to disclose: Consultant: Heron Therapeutics, Baudax Bio Speakers Bureau: Heron Therapeutics, Baudax Bio Scientific Advisory Boards: Heron Therapeutics, Baudax Bio
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-046-H08-P. The activity is available for CE credit through February 24, 2023.
This activity is supported by an educational grant from Heron. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives
Discuss the role of disruptions in the gut microbiome in the development of Clostridioides difficile infection (CDI) and recurrent CDIs
Review the efficacy, safety, and role of fecal microbiota transplantation and emerging microbiome-based drugs for treatment of CDIs and rCDIs
Faculty: Kevin W. Garey, PharmD, MS Professor and Chair University of Houston College of Pharmacy Houston, Texas
Kevin W. Garey, PharmD, MS, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Summit, Acurx, and Parakek Pharmaceuticals, and Seres Therapeutics Consultant: Ferring Pharmaceuticals
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-048-H01-P. The activity is available for CE credit through January 31, 2023.
This activity is supported by a medical education grant from Ferring Pharmaceuticals. Participants can claim credit for this CE activity by following the link below: https://www.pharmacytimes.org/courses/the-promising-role-of-microbiome-based-drugs-for-the-treatment-and-prevention-of-recurrent-clostridioides-difficile Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objective Identify best practices for managing toxicities associated with therapies for the treatment of Waldenström macroglobulinemia Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan
Faculty has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-457-H01-P. The activity is available for CE credit through June 20, 2022.
This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Recognize best practices for managing adverse effects associated with immune checkpoint inhibitor (ICI)-targeted therapy combinations Faculty: Jacob K. Kettle, PharmD, BCOP Pharmacy Manager Ellis Fischel Cancer Center Department of Pharmacy University of Missouri Health Care Columbia, Missouri Faculty, has the following financial relationships with commercial interests to disclose: Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI Consultant: Pfizer, Lilly
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-21-438-H01-P. The activity is available for CE credit through December 17, 2022. This activity is supported by educational grants from Eisai Inc and Exelixis, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices
Educational Objectives · Describe the role of immune checkpoint inhibitor (ICI)-targeted therapy combinations across malignancies · Recall knowledge of ICI-targeted therapy combinations to treatment selection in patients with cancer Faculty: Jacob K. Kettle, PharmD, BCOP Pharmacy Manager Ellis Fischel Cancer Center Department of Pharmacy University of Missouri Health Care Columbia, Missouri
Faculty, has the following financial relationships with commercial interests to disclose: Jacob Kettle, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Speakers Bureau: Genentech, Merck, Amgen, Lilly, DSI Consultant: Pfizer, Lilly
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-437-H01-P. The activity is available for CE credit through December 17, 2022. This activity is supported by educational grants from Eisai Inc and Exelixis, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices
Pharmacy Times Continuing Education™ (PTCE) provides industry-leading pharmacy CE to retail, oncology, managed care, specialty, and health-system pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Podcast 1: Waldenström Macroglobulinemia and Treatment Advancements with the Use of BTK Inhibitors Educational Objectives · Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies · Review clinical guidelines and treatment selection in patients with WM
Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Ambulatory Hematology Oncology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Faculty has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022. This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc; and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices
Optimizing Care for People Living with HIV: Beyond Typical Risk Factors for Weight Gain | PTCE Connect Educational Objectives Describe recent data surrounding weight gain among people living with HIV (PLWH) who are on antiretroviral therapy Recognize the role of the pharmacist in the care of PLWH Continuing the Conversation – Individualizing the Management of HIV: A Focus on Weight Gain Introduction of faculty, affiliations, and disclosures Dr. David Koren, PharmD, MPH, BCPS, AAHIVP, Clinical Pharmacist Specialist in Infectious Diseases at the Temple University Health System, Philadelphia, Pennsylvania Dr. Koren has the following relevant financial relationships with commercial interests to disclose: Advisory Boards: Gilead, Thera, and ViiV Independent consulting: AbbVie and Thera Accreditation and support statement PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 credit hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. Access PTCE here: https://www.pharmacytimes.org/on-demand/continuing-the-conversation-individualizing-the-management-of-hiv-a-focus-on-weight-gain See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Educational Objectives: Discuss the various barriers to COVID-19 vaccine uptake including reasons for vaccine hesitancy Review how pharmacists can address the reluctance of COVID-19 vaccination in communities
Faculty:
Rachel Armstrong, PsyD
Clinical Psychologist
Portsmouth, NH
Rachel Armstrong, PsyD, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-283-H06-P. The activity is available for CE credit through July 29, 2022.
This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Adverse Effects versus Convenience of the COVID-19 Viral-Vector Vaccines
Educational Objectives: Articulate the benefits of viral-vector vaccines compared with the risk of thrombosis with thrombocytopenia syndrome (TTS) Elaborate on current viral-vector TTS adverse effect incidence data and risk among patients who have received or will receive a viral-vector vaccine
Faculty:
James Lewis, PharmD, FIDSA
ID Clinical Pharmacy Supervisor
Oregon Health & Sciences University
Portland, Oregon
James Lewis, PharmD, FIDSA, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-264-H06-P. The activity is available for CE credit through June 29, 2022.
This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Implementing Digital Technology Tools within Health-Systems for Improving Adherence and Patient Support
Educational Objectives: At the completion of this activity, participants will be able to: Define the pharmacist’s role in implementing digital and telemedicine technologies within the health system to improve adherence and provide remote patient monitoring and management.
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan
He has no relevant financial relationships with commercial interests to disclose.
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit.
Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part2
This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene.
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Foundations of Evidence for the Use of BTK Inhibitors in B-Cell Malignancies and Management Strategies for Cardiac and Bleeding Adverse Effects
Educational Objectives: At the completion of this activity, participants will be able to: Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data Recognize pharmacists’ responsibilities for monitoring and managing cardiac adverse effects specific to different health-system practice types
Anthony J. Perissinotti, PharmD, BCOP is a Clinical Pharmacist Specialist, Hematology and the Clinical Team Leader Hematology/Oncology as well as an Adjunct Clinical Assistant Professor at the University of Michigan - Michigan Medicine in Ann Arbor, Michigan
He has no relevant financial relationships with commercial interests to disclose.
PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours of knowledge-based credit.
Click here to view the activity on the PTCE website and claim your credit: https://www.pharmacytimes.org/on-demand/bcell-malignancies-podcast-part1
This activity is supported by educational grants from Pharmacyclics LLC., an AbbVie Company and Janssen Biotech, Inc and Beigene.
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Continuous Glucose Monitoring:Understanding the Pharmacist’s Role in Patient Education and Improving Outcomes in Diabetes Management Objectives
Describe the use of continuous glucose monitoring (CGM) in diabetes management and ADA/AACE recommendations Recognize the role of the pharmacist in providing education related to the use of CGM devices and interpreting CGM data
Faculty Disclosures
Curtis L. Triplitt, PharmD, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Bayer
Speaker’s Bureau: Eli Lilly, NovoNordisk
Susan Cornell, PharmD, CDCES, FAPhA, FADCES, has the following relevant financial relationships with commercial interests to disclose:
Speaker’s Bureau: Novo Nordisk, Inc.
Other Support: Advanced Practitioner Advisory Board- Novo Nordisk, Inc. PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for .5 contact hours of knowledge-based credit.
This activity is supported by an independent educational grant from Abbott Diabetes Care Inc.
Learn more here: https://www.pharmacytimes.org/on-demand/continuous-glucose-monitoring-understanding-the-pharmacists-role-in-patient-education-and-improving-outcomes-in-diabetes-management Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices
Pharmacy Connect Podcast: PCSK9 Inhibitors
Title: PCSK9 Inhibitors:Understanding the Pharmacist’s Role in Patient Education and Improving Outcomes With Hyperlipidemia Management
Special guest: Joseph Saseen, PharmD
Professor and Vice Chair, Clinical and Academic Programs; Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Objectives Understand the role of PCSK9 inhibitors in the American Heart Association and the American College of Cardiology hyperlipidemia management guidelines Review the pertinent drug information and clinical benefits of the use of PCSK9 inhibitors in the treatment of hyperlipidemia. Describe the role of the pharmacist in patient education and counseling on PCSK9 inhibitors for the treatment of hyperlipidemia through motivational interviewing.
CE LINK HERE:
https://www.pharmacytimes.org/on-demand/pcsk9-inhibitors-understanding-the-pharmacists-role-in-patient-education-and-improving-outcomes-with-hyperlipidemia-management
PTCE - Pharmacy Times Continuing Education
See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices